Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER4 | P35408 | 1/20 | 0.40 |
| ▸ | CREBBP | Q92793 | 3/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.35 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.35 |
| ▸ | IRAK4 | Q9NWZ3 | 4/20 | 0.35 |
| ▸ | KCNJ6 | P48051 | 2/20 | 0.35 |
| ▸ | KCNJ5 | P48544 | 2/20 | 0.35 |
| ▸ | KCNJ3 | P48549 | 2/20 | 0.35 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.34 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.34 |
| ▸ | PRKDC | P78527 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.34 |
| ▸ | MGLL | Q99685 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | CFTR | P13569 | 1/20 | 0.33 |
| ▸ | BRD4 | O60885 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29704418 | 1.00 | PTGER4 (0.40) | PTGER4CREBBPMAPK1SSTR4IRAK4 | |
| SCHEMBL31153524 | 0.86 | CFTR (0.39) | CREBBPMAPK1SSTR4KCNJ6KCNJ5 | |
| SCHEMBL26098592 | 0.81 | PTGER4 (0.39) | PTGER4CREBBPIRAK4KDM4CPRKDC | |
| SCHEMBL31153458 | 0.78 | TUBB4A (0.38) | PTGER4CREBBPIRAK4KCNJ6KCNJ5 | |
| SCHEMBL23530017 | 0.78 | PDE4D (0.41) | PTGER4MAPK1IRAK4 | |
| SCHEMBL29550149 | 0.78 | PDE4D (0.41) | PTGER4MAPK1IRAK4 | |
| SCHEMBL29704358 | 0.77 | CNR2 (0.46) | CREBBPSSTR4OPRK1KDM4CPRKDC | |
| SCHEMBL19644534 | 0.77 | CNR2 (0.46) | CREBBPSSTR4OPRK1KDM4CPRKDC | |
| SCHEMBL19644454 | 0.76 | OPRK1 (0.38) | PTGER4MAPK1SSTR4IRAK4KCNJ6 | |
| SCHEMBL23529922 | 0.75 | PTGER4 (0.42) | PTGER4MAPK1ALDH1A1HPGDHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026090317-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. (US) | 2026-04-30 | — | — | WO | disclosed |
| EP-4698544-A1 | COMPOUNDS AND USES THEREOF | Foghorn Therapeutics Inc. (US) | 2026-02-25 | — | — | EP | disclosed |
| WO-2024220946-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. (US) | 2024-10-24 | — | — | WO | disclosed |
| EP-4067347-B1 | HETEROCYCLIC INHIBITORS OF CBP/EP300 FOR THE TREATMENT OF CANCER | GENENTECH INC (US) | 2024-06-19 | — | — | EP | disclosed |
| EP-4067347-A1 | HETEROCYCLIC INHIBITORS OF CBP/EP300 FOR THE TREATMENT OF CANCER | Genentech, Inc. (US) | 2022-10-05 | — | — | EP | disclosed |
| CN-115028617-A | Heterocyclic inhibitors of CBP/EP300 and their use in the treatment of cancer | 基因泰克公司 | 2022-09-09 | — | — | CN | disclosed |
| CN-109476641-B | Heterocyclic inhibitors of CBP/EP300 and their use in the treatment of cancer | 基因泰克公司 | 2022-07-05 | — | — | CN | disclosed |
| US-11168070-B2 | Therapeutic compounds and uses thereof | GENENTECH, INC. (US) | 2021-11-09 | — | — | US | disclosed |
| US-11168070-B2 | Therapeutic compounds and uses thereof | GENENTECH, INC. (US) | 2021-11-09 | — | — | US | disclosed |
| US-20200399244-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2020-12-24 | — | — | US | disclosed |
| US-20200399244-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2020-12-24 | — | — | US | disclosed |
| US-10696655-B2 | Therapeutic compounds and uses thereof | GENENTECH, INC. (US) | 2020-06-30 | — | — | US | disclosed |
| US-10696655-B2 | Therapeutic compounds and uses thereof | GENENTECH, INC. (US) | 2020-06-30 | — | — | US | disclosed |
| US-20190152949-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2019-05-23 | — | — | US | disclosed |
| US-20190152949-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2019-05-23 | — | — | US | disclosed |
| WO-2017205536-A2 | THERAPEUTIC COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2017-11-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200399244-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | EP300, HDAC1, HDAC3 | PTGER4 965/4885CREBBP 7/4885MAPK1 909/4885 |
| US-20190152949-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | EP300, HDAC1, HDAC11 | PTGER4 964/4885CREBBP 6/4885MAPK1 753/4885 |
| US-11168070-B2 | Therapeutic compounds and uses thereof | EP300, HDAC1, HDAC11 | PTGER4 964/4885CREBBP 6/4885MAPK1 753/4885 |
| US-10696655-B2 | Therapeutic compounds and uses thereof | EP300, HDAC1, HDAC11 | PTGER4 964/4885CREBBP 6/4885MAPK1 753/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.